An experimental vaccine expressing wild-type p53 induces protective immunity against glioblastoma cells with high levels of endogenous p53. Export

@article{citeulike:2309436, abstract = {Inoculation of mice with a recombinant vaccinia virus expressing the full-length mouse wild-type p53 protein (Vp53-wt) was shown to induce partial protection against peripheral challenge with a mouse glioblastoma cell line, termed GL261, expressing high levels of nuclear, endogenous wild-type p53. In vivo experiments with knockout (KO) mice and mice treated with depleting doses of antibodies specific to lymphocyte subsets revealed that vaccine efficacy depended on CD4+ and CD8+ T cells as well as on natural killer (NK) cells. Vp53-wt virus-vaccinated mice that failed to develop tumours upon challenge with a minimal tumourigenic dose of GL261 cells remained completely resistant to further challenge with increased doses of GL261 cells. The efficacy of the Vp53-wt vaccine was improved by adding recombinant mouse interleukin-12 (rIL-12) as an adjuvant at the time of tumour challenge. The induction of T cells to p53 in Vp53-wt virus-immune mice was also demonstrated at the tumour site by immunochemistry and was further confirmed by a delayed-type hypersensitivity response to the p53 protein, although in vitro experiments using splenocytes from vaccinated mice failed to demonstrate CD4+ or CD8+ T-cell activity to p53.}, address = {The Wistar Institute, Philadelphia, PA 19104, USA.}, author = {Blaszczyk-Thurin, M. and Ertl, I. O. and Ertl, H. C.}, citeulike-article-id = {2309436}, citeulike-linkout-0 = {http://view.ncbi.nlm.nih.gov/pubmed/12234257}, citeulike-linkout-1 = {http://www.hubmed.org/display.cgi?uids=12234257}, issn = {0300-9475}, journal = {Scand J Immunol}, keywords = {glioblastoma, p53, retrovirus, vaccinia}, month = {October}, number = {4}, pages = {361--375}, posted-at = {2008-01-31 03:21:46}, priority = {2}, title = {An experimental vaccine expressing wild-type p53 induces protective immunity against glioblastoma cells with high levels of endogenous p53.}, url = {http://view.ncbi.nlm.nih.gov/pubmed/12234257}, volume = {56}, year = {2002} }

TY - JOUR ID - citeulike:2309436 L3 - citeulike-article-id:2309436 N2 - Inoculation of mice with a recombinant vaccinia virus expressing the full-length mouse wild-type p53 protein (Vp53-wt) was shown to induce partial protection against peripheral challenge with a mouse glioblastoma cell line, termed GL261, expressing high levels of nuclear, endogenous wild-type p53. In vivo experiments with knockout (KO) mice and mice treated with depleting doses of antibodies specific to lymphocyte subsets revealed that vaccine efficacy depended on CD4+ and CD8+ T cells as well as on natural killer (NK) cells. Vp53-wt virus-vaccinated mice that failed to develop tumours upon challenge with a minimal tumourigenic dose of GL261 cells remained completely resistant to further challenge with increased doses of GL261 cells. The efficacy of the Vp53-wt vaccine was improved by adding recombinant mouse interleukin-12 (rIL-12) as an adjuvant at the time of tumour challenge. The induction of T cells to p53 in Vp53-wt virus-immune mice was also demonstrated at the tumour site by immunochemistry and was further confirmed by a delayed-type hypersensitivity response to the p53 protein, although in vitro experiments using splenocytes from vaccinated mice failed to demonstrate CD4+ or CD8+ T-cell activity to p53. IS - 4 JF - Scand J Immunol SN - 0300-9475 AD - The Wistar Institute, Philadelphia, PA 19104, USA. EP - 375 TI - An experimental vaccine expressing wild-type p53 induces protective immunity against glioblastoma cells with high levels of endogenous p53. VL - 56 SP - 361 KW - glioblastoma KW - p53 KW - retrovirus KW - vaccinia AU - Blaszczyk-Thurin, M AU - Ertl, IO AU - Ertl, HC PY - 2002/10// UR - http://view.ncbi.nlm.nih.gov/pubmed/12234257 ER -